Dr. Paul Maloof, board-certified by the American Board of Orthopaedic Surgery, a foot and ankle doctor from Bergen County, New Jersey, joined Tidewater Orthopaedics in 2013. His choice to become an orthopaedic surgeon was inspired by a pediatrician, and his favorite part of his work is being able to change the quality of life of his patients in a very meaningful way.
Dr. Maloof began his path to orthopaedic surgery at Tufts University in Medford, Massachusetts, where he completed his undergraduate work. After spending three years in Steamboat Springs, Colorado, Dr. Maloof attended the University of Medicine and Dentistry of New Jersey for his medical doctorate and residency. While there, he served as administrative chief resident in one of the busiest Level I trauma centers on the east coast. Dr. Maloof then completed his fellowship training in foot and ankle surgery at Duke University in Durham, North Carolina.
Dr. Maloof brings many advanced treatments to Tidewater Orthopaedics as the only full-time foot and ankle orthopaedic surgeon in the region specializing in complex and comprehensive foot and ankle care, both surgical and nonsurgical. He aims to treat his patients in the most conservative manner, reserving surgery only for cases when nonsurgical management is no longer an option.
Foot and ankle doctor, Paul B. Maloof, M.D., sees patients in Hampton, VA as well as Williamsburg, VA.
Our foot and ankle doctor, Dr. Maloof, performs foot and ankle procedures like total ankle replacement, ankle arthroscopy, bunion correction, deformity correction, flatfoot reconstruction, foot drop, traumatic injuries, achilles tendon repair, and hammertoe correction.
Department of Medicine-Hematology/Oncology, UMDNJ-NJMS Summer 2002
Construction of expression vector to produce stable transfectants with selected siRNA’s. The novelty of this vector caused it to be names pPMSKH1 using my initials.
Research Teaching Specialist
Department of Medicine-Hematology/Oncology, UMDNJ-NJMS 1997 – 1998
Construction of cDNA libraries froom bone marrow cells and screening of clones related to the 7-transmembrane family of receptors. Significant Findings: I. Identified a novel humanspecific gene, HGFIN, now linked to cell cycle checkpoint, and under the control of p53. II. Identified fibronectin as a binding protein for a fibrogenic factor. Consequently, uncovered potential mechanism for bone marrow fibrosis.